Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomi... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial
0
Authors
Albert Oriol
19 more
Albert Oriol
•
Irwindeep Sandhu
17 more
•
Paul Richardson
Published
September 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Clinical Lymphoma Myeloma & Leukemia
Topics
Medicine
Cancer Oncology
Internal Medicine
Hematology
Organic Chemistry
Show all topics
DOI
10.1016/s2152-2650(24)00983-2
